Last reviewed · How we verify

Ibuprofen plus Omeprazole — Competitive Intelligence Brief

Ibuprofen plus Omeprazole (Ibuprofen plus Omeprazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID plus proton pump inhibitor combination. Area: Pain management / Gastroenterology.

marketed NSAID plus proton pump inhibitor combination COX-1/COX-2 (ibuprofen); H+/K+-ATPase (omeprazole) Pain management / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Ibuprofen plus Omeprazole (Ibuprofen plus Omeprazole) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Ibuprofen reduces inflammation and pain by inhibiting cyclooxygenase enzymes, while omeprazole protects the stomach by suppressing gastric acid production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ibuprofen plus Omeprazole TARGET Ibuprofen plus Omeprazole Pfizer's Upjohn has merged with Mylan to form Viatris Inc. marketed NSAID plus proton pump inhibitor combination COX-1/COX-2 (ibuprofen); H+/K+-ATPase (omeprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID plus proton pump inhibitor combination class)

  1. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ibuprofen plus Omeprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/ibuprofen-plus-omeprazole. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: